Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
EPHB3 Biologics Sequence Review Report 2026: Ephrin type-B receptor 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHB4 Biologics Sequence Review Report 2026: Ephrin type-B receptor 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHB4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHB1 Biologics Sequence Review Report 2026: Ephrin type-B receptor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA8 Biologics Sequence Review Report 2026: Ephrin type-A receptor 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA7 Biologics Sequence Review Report 2026: Ephrin type-A receptor 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA6 Biologics Sequence Review Report 2026: Ephrin type-A receptor 6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA3 Biologics Sequence Review Report 2026: Ephrin type-A receptor 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA2 Biologics Sequence Review Report 2026: Ephrin type-A receptor 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA4 Biologics Sequence Review Report 2026: Ephrin type-A receptor 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA5 Biologics Sequence Review Report 2026: Ephrin type-A receptor 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
EPHA1 Biologics Sequence Review Report 2026: Ephrin type-A receptor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of EPHA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADAMTS5 Biologics Sequence Review Report 2026: A disintegrin and metalloproteinase with thrombospondin motifs 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADAMTS5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.